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Specific measurement of PTH (1-84) in various forms of renal
osteodystrophy (ROD) as assessed by bone histomorphometry.
Background. Parathyroid hormone (PTH) measurements
serve as a noninvasive, diagnostic tool for the assessment of
renal osteodystrophy (ROD). Their value has been questioned
following reports indicating that all commercially available in-
tact PTH (I-PTH) assays cross-react with amino terminally trun-
cated PTH fragments. Because these fragments can account for
50% of total PTH, their detection will overestimate the true
PTH concentration and may lead to diagnostic inaccuracies.
The aim of this study was to evaluate the specific Bio-Intact
PTH (1-84) Assay (BI-PTH) in patients with various types of
ROD confirmed by bone biopsy.
Methods. Bone biopsies were taken from 132 patients with
chronic kidney disease (CKD) stages 3 to 5, and quantitative
bone histomorphometry was done. Plasma PTH levels were
measured using both the BI-PTH and I-PTH assays on an au-
tomated analyzer.
Results. Patients with CKD stages 3/4 and low turnover skele-
tal lesions had BI-PTH values (pg/mL, mean ± SD) of 35
(±34) and I-PTH values of 59 (± 63). Corresponding values for
BI-PTH and I-PTH in those with high turnover lesions were
141 (±60) and 221 (±106). Patients with CKD stage 5 and low
turnover skeletal lesions had BI-PTH and I-PTH levels of 51
(±38) and 90 (±60), respectively, whereas the corresponding re-
sults for BI-PTH and I-PTH in those with high turnover lesions
were 237 (±214) and 461 (±437). The areas under the receiver
operating characteristic (ROC) curves for distinguishing low
turnover from high turnover lesions were 0.94 for BI-PTH and
0.91 for I-PTH in CKD stages 3/4 and 0.86 for BI-PTH and 0.85
for I-PTH in CKD stage 5. Among all patients, BI-PTH levels
are approximately 50% lower than I-PTH levels, but the results
of the two assays are correlated highly (R2 = 0.92).
Conclusion. Plasma PTH measurements using either the BI-
PTH or I-PTH assay effectively identify patients with reduced
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bone turnover and serve to distinguish this subgroup from those
with high turnover lesions of renal bone disease. Both assays
provide better diagnostic discrimination for this purpose than
calculated values for the ratio of PTH (1-84)/amino terminally
truncated PTH fragments.
Renal bone disease encompasses a spectrum of disor-
ders ranging from the high turnover skeletal lesions of
secondary hyperparathyroidism that arise from persis-
tently elevated plasma parathyroid hormone (PTH) lev-
els to low turnover lesions that are associated with normal
or reduced plasma PTH values. The definitive standard
for the classification of renal osteodystrophy (ROD) is
bone histomorphometry, but this requires bone biopsy,
an invasive diagnostic procedure, and access to special-
ized laboratory services that are not available widely. As
such, less-costly, noninvasive, biochemical methods are
generally used to manage ROD in patients with chronic
kidney disease (CKD).
PTH is the major determinant of bone formation and
turnover in patients with CKD [1]. Accordingly, measure-
ments of PTH levels in serum or plasma have been used
for many years as a noninvasive biochemical method for
the initial diagnosis of renal bone disease and to monitor
its progression. Assays that measured PTH specifically
with less interference from carboxy-terminal fragments
were introduced with the advent of two-site immunomet-
ric technology in 1987 [2]. Such assays were thought to
measure the full-length hormone comprised of 84 amino
acids, or PTH (1-84), and thus came to be known as
“intact” PTH (I-PTH) assays. They were shown to be
superior for identifying patients with various histologic
subtypes of renal bone disease when compared to ra-
dioimmunoassays (RIA) that utilized single antibodies
directed toward epitopes located in the middle region
or carboxy-terminal portions of PTH [1]. In a study
of 259 patients undergoing dialysis regularly, Sherrard
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et al [3], Hercz et al [4], and Wang et al [5] reported
that I-PTH levels above 300 pg/mL were associated with
histologic evidence of osteitis fibrosa, whereas values
less than 100 pg/mL indicated adynamic ROD. Salusky
et al [6] also found histologic evidence of secondary hy-
perparathyroidism when I-PTH levels were above 250
to 300 pg/mL, whereas adynamic bone was seen com-
monly when values were below 150 pg/mL. Based upon
these observations and results from several other studies,
I-PTH values in the range of 150 to 300 pg/mL are consid-
ered to reflect relatively normal rates of bone formation
and turnover in patients undergoing dialysis as summa-
rized in the Kidney/Dialysis Outcomes Quality Initiative
(K/DOQI) guidelines of the National Kidney Foundation
(NKF) [7].
Several studies have shown, however, that first-
generation immunometric I-PTH assays not only detect
PTH (1-84) but also cross-react with other amino termi-
nally truncated PTH fragments such as PTH (7-84) [8, 9].
These findings prompted the development of more pre-
cise second-generation immunometric assays that do not
detect other PTH fragments or large peptides lacking one
or more amino terminal amino acid residues of PTH (1-
84) [10–13]. Because second-generation immunometric
PTH assays are now available for clinical use, it is impor-
tant to determine how these assays perform compared
to established I-PTH assays as predictors of bone histol-
ogy and bone turnover in patients with ROD. The cur-
rent study was done, therefore, to determine the range of
plasma PTH levels as measured by a second-generation
PTH assay, Nichols Advantage Bio-Intact PTH (1-84)
(BI-PTH), that are associated with various subtypes of
ROD as documented by bone histology in patients with
CKD and to compare the results with those obtained with
an established first-generation I-PTH assay, Nichols Ad-
vantage Intact PTH (I-PTH).
METHODS
Patients
A total of 132 unselected patients with CKD from
the eastern part of Germany were studied. Ninety-six
of them had CKD stage 5 and were undergoing treat-
ment at six different dialysis centers; 91 were managed by
hemodialysis and five were managed by peritoneal dialy-
sis. Two of the five patients undergoing peritoneal dialysis
were receiving continuous ambulatory peritoneal dial-
ysis (CAPD), whereas three were receiving continuous
cycling peritoneal dialysis (CCPD). Two patients under-
going hemodialysis at the time of study had been treated
previously with peritoneal dialysis, one with CAPD and
one with CCPD. A total of 36 patients had CKD stages
3 or 4 (CKD stages 3/4), as defined by current K/DOQI
guidelines [14].
The mean age (± SD) of patients was 54.0 (± 14.2)
years (range 21 to 80 years). There were 78 men and
54 women. Those undergoing dialysis had been treated
for an average of 44.9 (± 43.6) months (range 1 to
232 months). Hemodialysis was done three times a week,
and the length of each treatment ranged from 4 to 5 hours.
Known causes of CKD included glomerulonephritis (N =
34), diabetic nephropathy (N = 21), tubulointerstitial dis-
ease/analgesic nephropathy (N = 17), polycystic kidney
disease (N = 9), glomerulosclerosis (N = 9), and bilateral
nephrectomy (N = 5). Twelve cases were due to less com-
mon kidney diseases, whereas the cause of kidney failure
was unknown in 25 cases.
Nine patients had undergone parathyroidectomy at
various intervals prior to study, none during the preceding
6 months. Six of these patients had I-PTH levels greater
than 150 pg/mL, but the remaining three had I-PTH levels
below 50 pg/mL.
Fifty-two of the 132 patients were not being treated
with vitamin D sterols at the time of study, whereas 80
patients were receiving vitamin D as part of different
treatment regimens. Calcitriol [1,25(OH)2D3], alfacalcid-
iol [1a(OH)D3], and calcidiol [25(OH)D3] were the vita-
min D sterols utilized, and all were given orally. None of
the patients were treated with parenteral doses of vitamin
D. Forty-six of the 96 patients undergoing dialysis regu-
larly received phosphate-binding agents. Most were given
calcium-containing or aluminium-containing compounds
either alone or in combination. Nine patients were
treated with sevelamer. Three patients were receiving
prednisolone and six were receiving a bisphosphonate.
Biochemical determinations
Blood samples for biochemical determinations were
obtained on the day of bone biopsy for patients with
CKD stages 3/4, and immediately before dialysis during
the week preceding biopsy in those undergoing either
hemodialysis or peritoneal dialysis. Serum or plasma was
separated by centrifugation immediately after blood sam-
ples were collected and aliquots were stored at −80◦C.
Assays for BI-PTH and I-PTH used chemilumines-
cence methods on the Nichols Advantage autoanalyzer
(Nichols Institute Diagnostics, San Clemente, CA, USA).
The reference range for BI-PTH among persons with nor-
mal renal and parathyroid gland function is 8 to 50 pg/mL.
The intra-assay coefficient of variation is less than 4%
and the interassay coefficient of variation is less than
10%. The reference range for I-PTH is 10 to 65 pg/mL.
Intra- and interassay coefficients of variations are less
than 5.7% and less than 10%, respectively. A technical
and clinical comparison between the BI-PTH assay and
an established I-PTH assay has been reported by Inaba
et al [15].
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Serum creatinine was measured on a Beckman instru-
ment (Beckman Coulter Ltd., High Wycombe, UK) using
the Jaffe´ method. The results are expressed in micromole
per liter (lmol/L).
Bone biopsy and bone histomorphometry
Iliac crest bone biopsy was done under local anesthe-
sia in all patients. For those treated with hemodialysis, the
biopsy procedure was done on a nondialysis day. Ninety-
five of 132 patients, 24 with CKD stages 3/4 and 71 with
CKD stage 5, underwent double tetracycline labeling of
bone prior to biopsy using oral doses of oxytetracycline.
Cylindric samples of bone measuring 4 mm in diameter
were obtained with an electrical drill (Straumann Medi-
cal, Waldenburg, Switzerland) using a vertical approach
[16]. Specimens were fixed in Carnoy’s solution and em-
bedded in methylmethacrylate without decalcification.
Five micrometer sections were prepared for histologic
examination using several staining techniques, including
the Masson-Goldner, Giemsa, and Gomorri methods to
identify bone cells, bone marrow, and endosteal fibrosis
and to differentiate mineralized bone from osteoid. The
Prussian blue method [17, 18] was used to detect iron
deposition in bone, and the solochrome azurine method
[19–21] was used to detect aluminum.
Quantitative measurements of bone structure and
bone cells were done using a Merz ocular grid [22]
and the Osteoplan II Image Analysis System (Kon-
tron, Ecking, Germany). Areas and perimeters were
measured by point counting and by linear intersection
methods. Results are reported using standardized meth-
ods after Parfitt et al [23]. Trabecular bone volume
(BV) was expressed as a percentage of total tissue vol-
ume (TV), and osteoid volume (OV) was expressed as
a percentage of BV. Perimeter measurements for os-
teoid surface (OS), osteoblast-covered surface (ObS),
osteoclast-covered surface (OcS), mineralizing surface
(MS), as judged by the extent of tetracycline-labeled tra-
becular bone perimeter, and eroded surface (ES), which
represents the fraction of the trabecular bone perime-
ter occupied by Howship’s lacunae, were all expressed
as a percentage of the total bone surface (BS) (i.e., total
bone perimeter). Osteoid thickness (OTh) was measured
directly. Calculated dynamic parameters of bone forma-
tion included the mineral apposition rate (MAR) and the
bone formation rate (BFR).
Classification by histologic subtype of ROD was done
using histomorphometric criteria as suggested previously
which includes ratios for OV to BV, osteoid perimeter
to total bone perimeter, and eroded perimeter to total
bone perimeter [16, 24]. By these criteria, five histologic
subgroups were identified: osteitis fibrosa (OF), mild os-
teitis fibrosa (MOF), mixed uremic bone disease (MUD),
osteomalacia (OM), and adynamic bone disease (ABD)
Table 1. Classification of five histologic groups of renal
osteodystrophy dependent on different histomorphometric ratios
Normal valuesa MOF OF OM MUD ABD
OV/BV% 4.0 <8 <8 >12 >12
OS/BS% 16.7 <22 >16.5 >33 >33
ES/BS% 5.8 >11.6 >11.6 <11.6 >11.6
ObS/BS% 3.2 <8 >8 <3.2
OcS/BS% 2.1 <2.5 >5.3 <2.1
Abbreviations are: MOF, mild osteitis fibrosa; OF, osteitis fibrosa; OM,
osteomalacia; MUD, mixed uremic bone disease; ABD, adynamic bone disease;
OV, osteoid volume; BV, bone volume; OS, osteoid surface; BS, bone surface;
ES, eroded surface; ObS, osteoblast-covered surface; OcS, osteoclast-covered
surface.
aNormal values according to peak bone mass [30].
Table 2. Functional classification of bone turnover using the static
histologic parameters osteoclast-covered surface/bone surface
(OcS/BS) and osteoblast-covered surface/bone surface (ObS/BS)
OcS/BS% ObS/BS%
Low bone turnover <1 <1
Normal bone turnover <2.1 <3.2
High bone turnover >2.1 >3.2
(Table 1). Patients with skeletal lesions other than ROD
(non-ROD) were identified by reductions in BV, dam-
aged trabecular structures, and/or lack of osteoclastic le-
sions and endosteal fibrosis.
The classification of patients by bone turnover sta-
tus was done using both the ratio of osteoblast-covered
bone perimeter to total bone perimeter and the ratio of
osteoclast-covered bone perimeter to total bone perime-
ter (Table 2).
Statistical analyses
Data are presented as means ± 1 standard deviation
(SD). Two patients were excluded from analysis because
results for I-PTH or BI-PTH were not available. The
relationships between biochemical parameters were as-
sessed by linear regression analysis. Analysis of variance
(ANOVA) was used to assess differences in mean val-
ues between groups. The predictive value of PTH levels
for the diagnosis of specific types of renal bone disease
was expressed in terms of sensitivity and specificity. These
parameters were obtained by calculating receiver operat-
ing characteristics (ROC) curves and the areas under the
curves (AUC) using the Analyze-It program (Analyze-It
Software Ltd., Leeds, UK). Probability values less than
5% were considered to be statistically significant.
RESULTS
High turnover skeletal lesions of ROD were much
more common than low turnover lesions both in patients
with CKD stages 3/4 and in those with CKD stage 5
(Table 3). Most patients with high turnover lesions had
overt OF, whereas far fewer had mixed uremic osteodys-
trophy. Adynamic bone was seen in approximately two
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Table 3. The distribution of patients with various histologic subtypes of renal osteodystrophy (ROD) and corresponding values for Bio-Intact
parathyroid hormone (BI-PTH) assay [mean, standard deviation (SD), median, and range]
Low bone turnover Normal bone turnover High bone turnover
(N = 16) (N = 29) (N = 85)
OM ABD MOF Non-ROD OF MUD
CKD stages 3/4 (N = 1)a (N = 7)a (N = 15)a
BFR lm2/lm/year
Mean 1 24 55
SD ± 0 ± 15 ± 64
BI-PTH pg/mL
No. of patients 2 3 4 7c 16 3
Mean 15.6 47.5 40 91.7 138.5 170.4
SD ± 16.1 ± 39.7 ± 29.5 ± 58.2 ± 62.9 ± 46.7
Median 15.5 29.0 40.5 63.0 123.1 174.0
Range 4.2–27 20–93 4–75 21–171 21–235 122–215
CKD stage 5 (N = 5)a (N = 8)a (N = 49)a
BFR lm2/lm/year
Meanb 14 27 68
SD ± 9 ± 20 ± 61
BI-PTH pg/mL
No. of patients 3 8 11 7 58 8
Mean 46.0 53.0 85.6 90.3 215.0 435.6
SD ± 18.3 ± 44.7 ± 74.7 ± 104.5 ± 176.9 ± 351.7
Median 50.0 49.0 58.0 56 147.0 295.0
Range 26–62 10–149 16–243 4–314 4–675 152–1212
Abbreviations are: CKD, chronic kidney disease; BFR, bone formation rate; MOF, mild osteitis fibrosa; OF, osteitis fibrosa; OM, osteomalacia; MUD, mixed uremic
bone disease; ABD, adynamic bone disease.
aNumber of patients with low bone turnover, normal bone turnover, or high bone turnover who underwent tetracycline labelling.
bMean values differ among low bone turnover, normal bone turnover, and high bone turnover [P < 0.001 by analysis of variance (ANOVA)].
cTwo patients with high bone turnover in the non-ROD group.
thirds of patients with low turnover skeletal lesions both
in CKD stages 3/4 and in CKD stage 5 (Table 3). Osteo-
malacia accounted for the remainder of the low turnover
lesions in each group (Table 3).
Among those who underwent double-tetracycline la-
beling before iliac crest bone biopsy, measurements of the
rate of bone formation generally confirmed the method
for classifying patients according to bone turnover sta-
tus using static histologic criteria. For patients with
CKD stage 5, bone formation rates differed substantially
among those with high, normal, or low turnover skeletal
lesions (P < 0.005 by ANOVA). For patients with CKD
stages 3/4, bone formation rates also varied substantially
among the three groups, and mean values in each group
were quite similar to those for patients with CKD, stage
5. The differences in bone formation among patients with
CKD stages 3/4 were not statistically significant, however,
due largely to the small number of patients evaluated
(Table 3).
Plasma PTH levels, as determined using the BI-PTH
assay, were generally higher in patients with CKD stage 5
than in those with CKD stages 3/4 (Table 3). Mean values
of BI-PTH were 190 ± 199 pg/mL in patients with CKD
stage 5 and 106 ± 69 pg/mL in patients with CKD stages
3/4 when all histologic subtypes of ROD were considered
(P = 0.015). By comparison, I-PTH levels were 369 ±
404 pg/mL and 171 ± 117 pg/mL in patients with CKD
stage 5, and CKD stages 3/4, respectively (P < 0.01). As
expected, serum creatinine values differed in these two
groups averaging 357 ± 224 lmol/L in those with CKD
stages 3/4, and 729 ± 272 lmol/L in those with CKD stage
5. The difference in BI-PTH levels between patients with
CKD stages 3/4, and those with CKD stage 5 was most
apparent in subjects with high turnover skeletal lesions.
Values did not differ substantially between those with
normal or reduced bone turnover (Table 3).
Among those with CKD stages 3/4, plasma BI-PTH
levels were substantially higher in patients with OF or
mixed ROD than in subjects with either normal or re-
duced bone turnover (Table 3). This difference was also
seen among patients with CKD stage 5 where plasma
BI-PTH levels were again greater in patients with high
turnover skeletal lesions than in those with either normal
or reduced bone turnover (Table 3).
Among patients with CKD stages 3/4, most with histo-
logic evidence of adynamic bone, OM, or MOF had BI-
PTH values that fell within the range of normal for the
assay, although levels were below the lower limit of nor-
mal in some (Table 3). In contrast, most patients with high
turnover skeletal lesions had elevated levels of BI-PTH.
Nevertheless, some patients with low turnover skeletal
lesions had modestly elevated BI-PTH values, whereas
others with high turnover lesions had normal or reduced
BI-PTH levels (Tables 3 and 4).
Histochemical evidence of bone aluminum deposition
was found in 13 patients, one with CKD stages 3/4, and
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Table 4. Discriminant analysis of high bone turnover vs. low bone turnover of the three parameters Bio-Intact parathyroid (BI-PTH), intact
parathyroid hormone (I-PTH), and BI-PTH/(I-PTH − BI-PTH) ratio in the chronic kidney disease (CKD) stage 5 group (N = 78)
Cutoff Sensitivity% Specificity% Area under the curve
CKD stages 3/4
BI-PTH pg/mL 21 40 100 0.94
94 100 81 (N = 26)
I-PTH pg/mL 31 40 100 0.91
86 80 95 (N = 26)
183 100 67
BI-PTH/(I-PTH – BI-PTH) 0.76 0 100 0.54
1.38 60 76.2 (N = 26)
10.7 100 14.3
CKD stage 5
BI-PTH pg/mL 15 9 100 0.86
73 91 82 (N = 78)
149 100 53
I-PTH pg/mL 27 18 100 0.85
163 91 76 (N = 78)
243 100 62
BI-PTH/(I-PTH – BI-PTH) 0.8 22 100 0.55
0.96 91 38 (N = 78)
51 100 0
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Fig. 1. Values for Bio-Intact parathyroid hor-
mone (BI-PTH) (left) and intact parathy-
roid hormone (I-PTH) (right) in patients with
either high bone turnover (HTO) or low
bone turnover (LTO) skeletal lesions of re-
nal osteodystrophy. Results for patients with
chronic kidney disease (CKD) stages 3/4 (up-
per panels) and in those with CKD stage
5 (lower panels) are presented separately.
Dashed lines depict the range for I-PTH rec-
ommended by the K/DOQI guidelines of the
National Kidney Foundation for patients with
CKD stage 5.
12 with CKD stage 5. Three patients who were managed
by dialysis had extensive bone aluminum deposition as
judged by the fraction of the trabecular bone perimeter
staining positive for aluminum. Five had moderate bone
aluminium accumulation, whereas four had only mini-
mal evidence of aluminum deposition in bone. There was
no relationship, however, between the extent of bone
aluminum accumulation and bone turnover. The pro-
portion of patients with histochemical evidence of bone
aluminum deposition did not differ among the various
subtypes of ROD in patients with CKD stage 5.
Plasma PTH levels differed substantially between pa-
tients with high turnover or low turnover skeletal lesions
when assessed using either BI-PTH or I-PTH. This was
the case both in patients with CKD stages 3/4, and in those
with CKD stage 5 (Fig. 1). Mean values for I-PTH in pa-
tients with CKD stage 5 and high turnover lesions of ROD
exceeded the upper limit of the range recommended by
the K/DOQI guidelines from the NKF, whereas I-PTH
levels in those with low turnover lesions were, on aver-
age, below the lower limit of the recommended target
range.
Overall, there was a high degree of correlation between
the results obtained using the BI-PTH and I-PTH assays
(R2 = 0.92), across a wide range of plasma PTH val-
ues when data from all study participants were assessed
(Fig. 2). The slope (0.52) of the relationship indicates
that plasma PTH levels obtained using the BI-PTH as-
say are approximately 48% lower than those determined
using the I-PTH assay for the group as a whole. Among
those with CKD stages 3/4, the slope (0.59) of the linear
relationship between BI-PTH and I-PTH was slightly
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greater than that for patients with CKD stage 5, but the
difference was not statistically significant. Thus, plasma
PTH values determined using the BI-PTH assay are, on
average, 41% lower in patients with CKD stages 3/4, and
50% lower in patients with CKD stage 5, compared to
results obtained using the I-PTH assay.
Discrimination between patients with high turnover
lesions of ROD and those with low turnover skeletal
lesions was modestly better using the BI-PTH assay com-
pared to the I-PTH assay in patients with CKD stages
3/4 (Table 4). The two assays were nearly equivalent for
making this distinction among patients with CKD stage 5
(Table 4). The cutoff points representing 100% sensitiv-
ity, 100% specificity, and the highest sensitivity/specificity
combination for each subgroup of patients are depicted.
Estimates of the amount of amino terminally truncated
fragments of PTH (1-84) were calculated as reported pre-
viously by others, and the concentration of PTH (1-84)
relative to the concentration of amino terminally trun-
cated PTH fragments was determined. Results obtained
using either the BI-PTH assay or the I-PTH assay were
more effective than calculations of the ratio of PTH (1-
84)/amino terminally truncated PTH fragments for dis-
tinguishing between patients with either high turnover
or low turnover skeletal lesions both in CKD stages 3/4,
and in CKD stage 5.
Among patients with CKD stage 5, the ROC curves
for both the BI-PTH and I-PTH assays provided good
to excellent discrimination between patients with high
turnover or low turnover lesions of ROD (Fig. 3). Cal-
culated values for the ratio of PTH (1-84)/amino termi-
nally truncated PTH fragments were much less effective
in making this distinction (Fig. 3).
DISCUSSION
Measurements of the concentration of PTH in serum
or plasma are used widely as a noninvasive biochemical
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method for assessing bone turnover in patients with CKD
and for identifying individuals with various subtypes of
ROD. This became possible more than 20 years ago with
the introduction of double antibody immunometric PTH
assays which overcame many of the shortcomings of sin-
gle antibody RIAs for PTH that had been employed pre-
viously. Earlier RIAs commonly detected various frag-
ments of PTH that accumulate in the serum or plasma of
patients with CKD because their renal clearance and/or
degradation are diminished. Most of these peptides lack
some, or all, of the amino terminal region of PTH that is
responsible for binding to and initiating signal transduc-
tion through the type I PTH receptor. Such peptide frag-
ments have been considered traditionally to be biologi-
cally inactive, and their detection by PTH RIAs largely
explained the failure of such measurements to accurately
predict bone histology and bone turnover in patients with
CKD when assessed by quantitative bone histomorphom-
etry.
In contrast, immunometric assays for PTH detect rela-
tively large peptides and fail to detect most small amino
terminally truncated PTH fragments that are recognized
by many PTH RIAs. The value of immunometric PTH
assays as predictors of bone histology and bone turnover
in patients undergoing treatment with dialysis has been
established firmly, and the results serve as a key compo-
nent of management guidelines for renal bone disease.
The data are now somewhat dated, however, and may
not accurately reflect the skeletal response to current
therapeutic approaches which includes the use of large
parenteral doses of vitamin D sterols often together with
large oral doses of calcium in an effort to control serum
phosphorus levels. In addition, the demographics of the
current dialysis population in the United States, where
more than half of the patients are 65 years of age or older
and where nearly 50% are diabetic, differ substantially
from that of 15 to 20 years ago when immunometric PTH
assays were validated initially in cross-sectional studies
using bone histology.
It is now known that first-generation immunometric
assays such as the I-PTH assay detect not only PTH (1-
84) but also cross-react with certain amino terminally
truncated PTH fragments, including PTH (7-84) [8, 9]. In
contrast, second-generation PTH assays such as the BI-
PTH assay detect PTH (1-84) exclusively. Only limited
data are available, however, that describes the utility of
second-generation PTH assays for the diagnosis of renal
bone disease in patients undergoing dialysis. The current
cross-sectional study was done, therefore, to determine
the prevalence of the various histological subtypes of
ROD not only in patients with CKD stage 5 undergoing
dialysis but also in those with CKD stages 3/4. In addition,
the utility of a first-generation immunometric PTH as-
say, I-PTH, was compared to that of a second-generation
immunometric PTH assay, BI-PTH, for the diagnosis of
renal bone disease in each of these groups.
High turnover skeletal lesions of OF and mixed ROD
were the most common histologic findings in the current
study both in patients with CKD stage 5 and in those with
CKD stages 3/4. A much smaller number of patients had
low turnover lesions such as adynamic bone. The results
are thus qualitatively similar to those reported by Coen
et al [25] who detected adynamic bone in approximately
11% of patients evaluated by bone histomorphometry,
which included subjects with CKD stage 5 undergoing
dialysis and those with CKD stages 3/4. In contrast, Sher-
rard et al [3] and Hercz et al [4] found adynamic ROD
in nearly half of patients managed with hemodialysis and
in almost 60% of those undergoing peritoneal dialysis,
whereas Malluche, Mawad, andMonier-Faugere [26] re-
ported a substantial increase in the prevalence of ady-
namic bone during the past 10 years in patients managed
with dialysis.
The explanation for the difference among studies in the
distribution of the various histologic subtypes of ROD
is uncertain. The current investigation was done exclu-
sively, however, in patients treated in the eastern part of
Germany where intravenous doses of vitamin D sterols
are used much less often than in North America to treat
secondary hyperparathyroidism among patients under-
going hemodialysis. This therapeutic approach has been
implicated in the pathogenesis of adynamic bone, partic-
ularly when combined with the use of large oral doses of
calcium to manage phosphorus retention and hyperphos-
phatemia. None of the patients in the current study were
treated with intravenous doses of vitamin D sterols, and
nearly half of those undergoing dialysis were not receiv-
ing phosphate-binding medications. As such, relatively
few patients were exposed to large oral doses of cal-
cium as part of a phosphate-binding regimen. The smaller
proportion of diabetic patients in the current study may
also account for the lower prevalence of adynamic ROD
compared to other reports. Adynamic bone is common
in those with diabetes, whereas secondary hyperparathy-
roidism occurs much less frequently in diabetic subjects
than in patients with other causes of renal failure.
The current results are consistent with data presented
elsewhere indicating that plasma PTH levels determined
using the BI-PTH assay are approximately 50% lower
than those determined using the I-PTH assay in patients
undergoing hemodialysis [27, 28]. Similar findings have
been reported using another second-generation immuno-
metric PTH assay that detects PTH (1-84) exclusively [10,
12]. There are modest differences, however, between the
results obtained using the BI-PTH and I-PTH assays in
patients with CKD stage 5 and those with CKD stages 3/4.
Although BI-PTH values were 50% lower than I-PTH
values in subjects with CKD stage 5, the BI-PTH results
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were only 41% lower than I-PTH values in patients with
CKD stages 3/4. These modest differences may be due to
the greater retention of amino terminally truncated PTH
fragments among patients with advanced kidney failure
who require treatment with dialysis compared to those
with CKD stages 3/4. Additional work is required to clar-
ify this issue.
Recent guidelines for the management of bone disease
and mineral metabolism in patients with CKD suggest
that plasma PTH levels using the I-PTH assay be main-
tained within the range of 150 to 300 pg/mL in patients
with CKD stage 5 who are treated with dialysis [7]. The
recommendation is based on assessments of bone histol-
ogy in several hundreds of patients with CKD stage 5
in whom plasma PTH levels were determined using the
I-PTH assay in blood samples obtained at the time of
the bone biopsy procedure. Values in the range of 150 to
300 pg/mL corresponded generally with relatively normal
bone histology and with normal rates of bone formation
and turnover. Extrapolating from the results of the cur-
rent study which indicate that the BI-PTH assay provides
PTH values that are approximately 50% lower than those
obtained using the I-PTH assay, the range of PTH levels
as determined by the BI-PTH assay for dialysis patients
with normal bone turnover would be expected to be ap-
proximately 75 to 150 pg/mL.
The data obtained in patients with CKD stage 5 who
had bone biopsy evidence of normal bone turnover sup-
port this contention. Plasma PTH levels using the BI-
PTH assay averaged 86 ± 75 pg/mL among patients
with MOF and normal bone turnover. Values were 90 ±
105 pg/mL in subjects with normal bone turnover in as-
sociation with skeletal lesions other than ROD, primar-
ily osteoporosis. Plasma PTH values varied substantially,
however, among patients with normal bone turnover as
documented by bone histomorphometry, and values were
beyond the suggested target range in some patients. Simi-
lar variances have been reported by others in studies that
used the I-PTH assay as a predictor of bone histology
in CKD stage 5 where ongoing treatment with vitamin
D sterols may account for disproportionate reductions in
plasma PTH levels in some patients [25, 29]. Additional
studies enrolling larger numbers of subjects are thus re-
quired to further characterize the relationship between
bone histology and plasma PTH levels as determined by
the BI-PTH assay in patients with CKD stage 5 and to
define more precisely the range of BI-PTH values that
corresponds reliably with evidence of normal bone his-
tology and normal bone turnover in those treated with
dialysis.
As noted previously, the prevalence of adynamic bone
in patients undergoing dialysis has increased in recent
years. One report suggests that adynamic ROD increases
the risk of arterial calcification among patients with CKD
stage 5. It is important, therefore, to identify such patients
in order to limit this risk. The current results indicate that
PTH measurements using either the BI-PTH or I-PTH
assay effectively identify patients with reduced rates of
bone turnover and serve to distinguish this subgroup from
those with high turnover skeletal lesions. Both measure-
ments provide a high degree of diagnostic discrimination
between low turnover or high turnover skeletal lesions.
Each proved superior for this purpose when compared
to calculated values for the ratio between the level of
PTH (1-84) and the concentration of amino terminally
truncated PTH fragments. The diagnostic value of I-PTH
measurements for the assessment of patients with ROD
as established previously is thus retained when using the
BI-PTH assay that measures PTH (1-84) exclusively.
CONCLUSION
Plasma PTH measurements using a second-generation
immunometric assay that detects PTH (1-84) exclusively
provide qualitatively similar information to that reported
previously using a well-established first-generation im-
munometric PTH assay for the assessment of renal bone
disease. The BI-PTH assay may offer slightly better
discrimination between patients with low turnover or
high turnover lesions of ROD, but additional studies are
needed to address this matter adequately. The current
results indicate that measurements of PTH (1-84) are su-
perior to derived estimates such as the ratio of PTH (1-84)
to the concentration of amino terminally truncated PTH
fragments as a predictor of bone histology in patients with
CKD.
Reprint requests to Gabriele Lehmann, Clinic for Internal Medicine,
Erlanger Allee 101, 07747 Jena, Germany.
E-mail: gabriele.lehmann@med.uni-jena.de
REFERENCES
1. SOLAL ME, SEBERT JL, BOUDAILLIEZ B, et al: Comparison of intact,
midregion, and carboxy terminal assays of parathyroid hormone
for the diagnosis of bone disease in hemodialyzed patients. J Clin
Endocrinol Metab 73:516–524, 1991
2. NUSSBAUM SR, ZAHRADNIK RJ, LAVIGNE JR, et al: Highly sensitive
two-site immunoradiometric assay of parathyrin, and its clinical util-
ity in evaluating patients with hypercalcemia. Clin Chem 33:1364–
1367, 1987
3. SHERRARD DJ, HERCZ G, PEI Y, et al: The spectrum of bone disease in
end-stage renal failure—An evolving disorder. Kidney Int 43:436–
442, 1993
4. HERCZ G, PEI Y, GREENWOOD C, et al: Aplastic osteodystrophy with-
out aluminum: The role of “suppressed” parathyroid function. Kid-
ney Int 44:860–866, 1993
5. WANG M, HERCZ G, SHERRARD DJ, et al: Relationship between intact
1-84 parathyroid hormone and bone histomorphometric parameters
in dialysis patients without aluminum toxicity. Am J Kidney Dis
26:836–844, 1995
6. SALUSKY IB, RAMIREZ JA, OPPENHEIM W, et al: Biochemical
markers of renal osteodystrophy in pediatric patients undergoing
CAPD/CCPD. Kidney Int 45:253–258, 1994
7. NKF: K/DOQI Clinical Practice Guidelines for Bone Metabolism
and Disease in Chronic Kidney Disease Guideline 8B, in K/DOQI
Clinical Practice Guidelines for Bone Metabolism and Disease in
1214 Lehmann et al: PTH (1-84) levels and bone histomorphometry in CKD
Chronic Kidney Disease Guidelines, New York, National Kidney
Foundation, 2003
8. BROSSARD JH, CLOUTIER M, ROY L, et al: Accumulation of a non-
(1-84) molecular form of parathyroid hormone (PTH) detected
by intact PTH assay in renal failure: importance in the inter-
pretation of PTH values. J Clin Endocrinol Metab 81:3923–3929,
1996
9. LEPAGE R, ROY L, BROSSARD JH, et al: A non-(1-84) circulating
parathyroid hormone (PTH) fragment interferes significantly with
intact PTH commercial assay measurements in uremic samples. Clin
Chem 44:805–809, 1998
10. JOHN MR, GOODMAN WG, GAO P, et al: A novel immunoradiomet-
ric assay detects full-length human PTH but not amino-terminally
truncated fragments: Implications for PTH measurements in renal
failure. J Clin Endocrinol Metab 84:4287–4290, 1999
11. SLATOPOLSKY E, FINCH J, CLAY P, et al: A novel mechanism for skele-
tal resistance in uremia. Kidney Int 58:753–761, 2000
12. GAO P, SCHEIBEL S, D’AMOUR P, et al: Development of a novel
immunoradiometric assay exclusively for biologically active whole
parathyroid hormone 1-84: Implications for improvement of accu-
rate assessment of parathyroid function. J Bone Miner Res 16:605–
614, 2001
13. TERRY AH, ORROCK J, MEIKLE AW: Comparison of two third-
generation parathyroid hormone assays. Clin Chem 49:336–337,
2003
14. NFK: K/DOQI Clinical Practice Guidelines for Chronic Kidney
Disease: Evaluation, classification, and stratification. Am J Kidney
Dis 39:S1–S266, 2002
15. INABA M, NAKATSUKA K, IMANISHI Y, et al: Technical and clinical
characterization of the Bio-PTH (1-84) immunochemiluminometric
assay and comparison with a second-generation assay for parathy-
roid hormone. Clin Chem 50:385–390, 2004
16. MALLUCHE HH, MONIER-FAUGERE MC: The role of bone biopsy in
the management of patients with renal osteodystrophy. J Am Soc
Nephrol 4:1631–1642, 1994
17. SHEEHAN DC, HRAPCHAK BB: Theory and Practice of Histotechnol-
ogy, 2nd ed., Columbus (Ohio), Battelle Press, 1987
18. ROMEIS B: Mikroskopische Technik, 17th ed., Munic, Vienna, Balti-
more, Urban and Schwarzenberg, 1989
19. DENTON J, FREEMONT AJ, BALL J: Detection and distribution of alu-
minium in bone. J Clin Pathol 37:136–142, 1984
20. FERNANDEZ-MARTIN JL, MENENDEZ P, ACUNA G, et al: Staining of
bone aluminium: Comparison between aluminon and solochrome
azurine and their correlation with bone aluminium content. Nephrol
Dial Transplant 11 (Suppl 3):80–85, 1996
21. KAYE M, HODSMAN AB, MALYNOWSKY L: Staining of bone for alu-
minum: Use of acid solochrome azurine. Kidney Int 37:1142–1147,
1990
22. MERZ WA, SCHENK RK: Quantitative structural analysis of human
cancellous bone. Acta Anat (Basel) 75:54–66, 1970
23. PARFITT AM, DREZNER MK, GLORIEUX FH, et al: Bone histomor-
phometry: Standardization of nomenclature, symbols, and units. Re-
port of the ASBMR Histomorphometry Nomenclature Committee.
J Bone Miner Res 2:595–610, 1987
24. MALLUCHE HH, FAUGERE M-C: Atlas of Mineralized Bone Histology,
New York, Basel, S. Karger, 1986
25. COEN G, BALLANTI P, BONUCCI E, et al: Renal osteodystrophy in pre-
dialysis and hemodialysis patients: Comparison of histologic pat-
terns and diagnostic predictivity of intact PTH. Nephron 91:103–
111, 2002
26. MALLUCHE HH, MAWAD H, MONIER-FAUGERE MC: The importance
of bone health in end-stage renal disease: Out of the frying pan, into
the fire? Nephrol Dial Transplant 19 (Suppl 1):i9–i13, 2004
27. SAVOCA R, BOCK A, KRAENZLIN ME, et al: An automated “bio-
intact” PTH assay: A step towards standardisation and improved
correlation with parathyroid function in renal disease. Clin Chim
Acta 343:167–171, 2004
28. MARTIN KJ, AKHTAR I, GONZALEZ EA: Parathyroid hormone: New
assays, new receptors. Semin Nephrol 24:3–9, 2004
29. MONIER-FAUGERE MC, MALLUCHE HH: Trends in renal osteodystro-
phy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol
Dial Transplant 11 (Suppl 3):111–120, 1996
30. DELLING G: Endocrine bone diseases, morphology, histomorphom-
etry and differential diagnosis. Vero¨ff Pathol 98:1–111, 1975
